Incretin Therapies for Patients with Type 2 Diabetes and Chronic ...

The first report on direct effects of dual GLP-1/GIP receptor agonism on the kidneys comes from a prespecified exploratory analysis of the ...

The glucose-lowering effects of GLP-1 agonists and DPP-4 inhibitors make incretin-related therapies well suited to patients with poor glycemic ...

Incretin-Based Therapies in Type 2 Diabetes Mellitus

Exenatide (synthetic exendin-4) is the only GLP-1R agonist approved by regulatory agencies as an adjunct therapy to patients with T2DM not achieving ...

Incretin-Based Therapies for the Treatment of Type 2 Diabetes

2). There are now over a dozen long-acting investigational GLP-1R agonists being developed for the treatment of type 2 diabetes (8). Several ...

Incretin Based Treatments - Diabetes Education Online - UCSF

GLP- 1 analogs are injected medicines for people with type 2 diabetes that helps prevent the blood sugar from rising after eating. GLP- 1 analogs act like a ...

Safety and Efficacy of Incretin-Based Therapies in Patients With ...

In patients with moderate or severe CKD, incretin-based therapies are effective in reducing HbA 1c levels. Hypoglycemic events are rare.

Effect of Long-term Incretin-Based Therapies on Ischemic Heart ...

Patients with type 2 diabetes mellitus (T2DM) experience many cardiovascular complications. Several studies have demonstrated the ...

Safety and Efficacy of Incretin-Based Therapies in Patients With ...

INDEX WORDS: Type 2 diabetes mellitus (T2DM); chronic kidney disease (CKD); systematic review; epidemiology; meta-analysis; pharmacoepidemiology ...

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to ...

Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of their efficacy, ...

Efficacy and Safety of Incretin-Based Therapies in Patients with Type ...

Incretin-based therapies enhance endogenous insulin secretion without causing hypoglycemia or weight gain. This review focuses on the efficacy ...

Incretin based treatments and mortality in patients with type 2 diabetes

Conclusions Current evidence does not support the suggestion that incretin based treatment increases all cause mortality in patients with type 2 ...

Evidence‐based treatment of hyperglycaemia with incretin therapies ...

Current evidence supports an individualized approach to glycaemic management in patients with type 2 diabetes and advanced CKD, taking account of the needs of ...

Incorporating Incretin-Based Therapies into Clinical Practice for ...

Data indicate and clinical experience confirms that incretins are well tolerated in appropriate patients and provide sustained glycemic control ...

Effects of Incretin-Based Therapies on Diabetic Microvascular ...

Potential benefits of incretin-based therapies such as glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) ...

Clinical Application of Incretin-Based Therapy: Therapeutic Potential ...

Early use of these agents may be effective in preventing diabetes in those at risk, or in halting or retarding disease progression in patients with frank ...

The efficacy of incretin therapy in patients with type 2 diabetes ...

During treatment with incretin therapies, severe hyperglycemia and ketosis were not observed in any patients. Maximum blood glucose and mean ...

Incretin Therapies for Patients with Type 2 Diabetes and Chronic ...

Incretin effects on structural kidney damage observed in diabetic kidney ...

Treating Patients With Type 2 Diabetes -- Incretin-Based Therapies

How do you choose between the incretin-based therapies, and where do they fit into the treatment algorithm of T2DM? Authors: Frank Svec, MD, PhD.

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to ...

Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of ...

Incretin-based therapy: a powerful and promising weapon in the ...

Incretin-based treatment modalities, and in particular glucagon-like peptide 1 (GLP-1) receptor agonists, are able to successfully counteract several of the ...